Shares of West Pharmaceutical Services Inc. soared in pre-market trading on Thursday, after the medical device company reported better-than-expected third-quarter earnings and raised its full-year guidance.
For the third quarter of 2024, West Pharmaceutical posted adjusted earnings per share of $1.85, beating the consensus estimate of $1.50 among analysts. The company's revenue of $746.9 million also topped Wall Street's projection of $709.616 million.
Following the strong quarterly results, West Pharmaceutical raised its full-year 2024 net sales guidance to a range of $2.875 billion to $2.905 billion, compared to its prior guidance of $2.87 billion to $2.9 billion and the consensus estimate of $2.874 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.